Preparing for Market: Reimbursement Strategies for Cell and Gene Therapies
Published 08 September 2017
In this interview with Regulatory Focus, Ted Slocomb and Michael Werner, two leaders from the Alliance for Regenerative Medicine (ARM), provide insight into future challenges and opportunities for ensuring market access and value-based reimbursement for gene and cell therapies.
Categories: Features, US, FDA, Biologics and biotechnology, Human cell and tissue, Reimbursement
Tags: Regenerative Medicine, ARM, Michael Werner, Ted Slocomb
Senate Bill Seeks to Create Standards Body for Regenerative Medicine
By Michael Mezher -
Published 15 January 2016
Sen. Tammy Baldwin (D-WI) introduced a bill on Tuesday to promote the development of regulatory science and standards for regenerative medicine and advanced therapies.
Categories: News, US, CBER, Biologics and biotechnology, Government affairs, Human cell and tissue
Tags: Gene therapy, Cell therapy, Regenerative medicine, Advances therapies, Senator Tammy Baldwin, Michael Werner